VGLL4 Antikörper (AA 220-270) (Biotin)

Produktnummer ABIN1401331

Produktdetails anti-VGLL4 Antikörper (Biotin)

Target: VGLL4 (Vestigial Like 4 (VGLL4))

Bindungsspezifität: AA 220-270

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser VGLL4 Antikörper ist konjugiert mit Biotin

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Kreuzreaktivität: Human, Maus, Ratte

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human VGLL4

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
IHC-P 1:200-400

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C for 12 months.

Haltbarkeit: 12 months

Details zu VGLL4

Target: VGLL4 (Vestigial Like 4 (VGLL4))

Andere Bezeichnung: VGLL4 (VGLL4 Produkte)

Hintergrund:

Synonyms: Transcription cofactor vestigial like protein 4, Vestigial like protein 4, VGL 4, VGLL4, VGLL4_HUMAN.

Background: The transcriptional enhancer factor-1 (TEF-1) family of transcription factors regulate tissue-specific gene expression in muscle and placenta. The mechanism whereby TEF-1 confers tissue specificity depends largely on the interaction of TEF-1 with tissue-specific cofactors. Transcription cofactor Vgl-4 (vestigial-like protein 4) is a 290 amino acid nuclear protein that interacts with TEF-1 and MEF-2. Vgl-4 is the only member of the vestigial-like family that is expressed in heart. Overexpression of Vgl-4 in cardiac myocytes interferes with basal expression and ?-adrenergic receptor-dependent activation of a TEF-1 dependent skeletal ?actin promoter. This suggests that Vgl-4 counteracts ?-adrenergic activation of gene expression in cardiomyocytes. There are two isoforms of Vgl-4 that are produced as a result of alternative splicing events.

Gen-ID: 9686

UniProt: Q14135